Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Barton hearing

This article was originally published in The Tan Sheet

Executive Summary

Barton hearing: House Commerce/oversight subcommittee to hear testimony from patients of Stanislaw Burzynski, MD, at a Feb. 29 hearing on cancer patients' access to experimental drugs. Burzynski, who has been conducting clinical trials of an unconventional "anti-neoplaston" cancer therapy in 300 terminal patients, is under federal grand jury indictment for 75 counts of FDA violations, mail fraud and contempt ("The Tan Sheet" Nov. 27, 1995, p. 12). According to a Commerce document, the patients currently await the decision of a Texas federal court judge regarding the future of the Burzynski Institute, and in turn, their ability to continue with the controversial treatment. Subcommittee Chairman Joe Barton (R-Tex.) has held up Burzynski as a "victim" of the legal system ("The Tan Sept. 18, 1995, p. 8), suggesting the need for FDA reform ("The Tan Nov. 20, 1995, p. 20)...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084811

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel